Exosomes: the new frontier of cell regeneration

[INDICE:h2]

For years, advanced skincare revolved around a few major players: hyaluronic acid, vitamin C, retinol, and peptides. Today, one word is appearing more and more often, both in aesthetic medicine protocols and in high-tech serums: exosomes. You will find them mentioned alongside treatments for enlarged pores, dark spots, fine lines, and dull skin, often with promises of complete skin regeneration. But what are they really, and what do the scientific data say instead of the marketing?

The short answer, before anything else: exosomes are not an active ingredient comparable to niacinamide or retinol. The same term encompasses biologically very different materials, most studies concern medical procedures rather than creams, and in Europe, exosomes of human origin are not even permitted in cosmetics.

What are exosomes?

Exosomes are extracellular vesicles produced by the body that transfer information between cells: microRNAs, growth factors, proteins, and lipids. Cells release them into their surroundings to communicate with one another, like biological nanopackages that transport messages.

The vesicles we now call exosomes were observed in the early 1980s while studying the maturation of reticulocytes, the precursors of red blood cells. At first, they appeared to be a system the cell used to get rid of material that was no longer useful. Only later did scientists realize that they also participate in communication between cells. This is where the interest of regenerative medicine—and, in turn, aesthetic dermatology—comes from.

In the context of the skin, this means they can influence key processes: the production of collagen and elastin, the inflammatory response, tissue repair, the management of oxidative stress, and pigmentation.

You often hear people talk about “stem cell exosomes,” and this is where the confusion begins. Stem cells are one of the main factories of exosomes. In recent years, many researchers have shifted their focus from using stem cells directly to using their vesicles, because this makes it possible to harness part of their regenerative potential while reducing the risks associated with cell manipulation.

Exosome or extracellular vesicle? The distinction that almost no one makes

The scientific community itself calls for caution regarding names. The MISEV2023 guidelines of the International Society for Extracellular Vesicles recommend using the general term “extracellular vesicles” when the cellular origin and the pathway through which the vesicle formed have not been precisely demonstrated.

“Exosome” in fact refers to a specific subpopulation, generated through a particular pathway within the cell. Demonstrating this requires characterization and controls that cannot be taken for granted. In cosmetics, however, the term is used as an umbrella term for vesicles, extracts, delivery systems, or technologies that imitate their function.

This flexibility does not mean that the product is ineffective. It means that neither its composition nor its activity can be inferred from the name. The same distinction applies to any ingredient: what matters is what is in the formula, not what it is called on the label.

Human, plant, bacterial, or “inspired”: they are not the same thing

The source is the first piece of information that should accompany every product, and it changes everything.

Vesicles of human origin

Most studies in aesthetic dermatology use vesicles obtained from mesenchymal cell cultures—adipose tissue, umbilical cord—or from platelets. These are biologically complex materials, whose composition also depends on culture conditions, and they raise issues concerning microbiological control, purity, contaminants, and reproducibility.

They are also, as we will see, the ones that cannot be used in a European cosmetic product.

Vesicles of plant origin

These are the ones most often found in cosmetics: extracellular-vesicle-like particles obtained from fruit, leaves, and roots. They are interesting both for their potential to transport bioactive substances and for their compatibility with a plant-based and biotechnological positioning.

Calling them “plant exosomes” is intuitive but not entirely accurate: plants have structures and formation pathways that do not match those of animal cells. Much of the data concerns cellular or animal models, and clinical studies on the finished cosmetic product are still limited.

There is also a practical problem: plant microvesicles are fragile, and often do not withstand heat, time, and packaging well.

Bacterial or fermentation-derived vesicles

Bacteria and microorganisms also release vesicles. Fermentation makes it possible to produce them in a more controlled and scalable way, but claiming a biotechnological origin does not demonstrate a benefit: the species used, culture conditions, purification, and safety profile remain decisive.

Exosome-like or exosome-inspired technologies

Some formulas do not contain isolated biological vesicles, but lipid systems designed to imitate a transport function. They may be valid technologies, but they should be described for what they are. A liposome does not become an exosome just because it resembles one in size.

What effects have been observed

Reviews published in recent years describe encouraging results for wrinkles, elasticity, hydration, pigmentation, acne scars, and recovery after procedures. A 2026 systematic review dedicated to skin rejuvenation included twenty-one studies and found signals consistent with a possible increase in collagen and elastin and a reduction in oxidative stress.

In terms of mechanisms, several types of vesicles — often derived from mesenchymal stem cells or fibroblasts — are able to:

• stimulate the synthesis of type I and III collagen and elastin;
• reduce the activity of matrix metalloproteinases (MMPs), which are responsible for the degradation of the extracellular matrix;
• improve hydration and barrier function;
• modulate hyperpigmentation by supporting cell turnover and influencing melanocytes and keratinocytes.

The point that changes everything: those studies are not about a cream

This is the key point to understand, and it is the one that always gets lost in marketing. A significant portion of the studies combines vesicles with fractional lasers, microneedling, or radiofrequency microneedling. These procedures create microchannels or temporarily alter the barrier, facilitating penetration — and they already produce a skin response on their own.

A concrete example. In a 2020 randomized split-face study of twenty-five people with acne scars, the entire face was treated with a fractional CO₂ laser; one side then received a gel containing adipose-derived exosomes and the other a control gel. The side with exosomes improved more. This is an interesting result, but it says only one thing: on skin already microperforated by the laser, that gel works better than the control. It says nothing about a cream applied to intact skin.

The same applies to a twelve-week prospective randomized study of adipose-derived vesicles combined with microneedling for facial aging: the signals were positive, but the effects of the procedure and the biological material cannot be separated or extrapolated to at-home use.

In addition, many studies involve only a few dozen participants, have short follow-up periods, and use preparations that differ in origin, concentration, and characterization. Shared standards are lacking: there is no way to truly compare “one billion vesicles” in one product with the same stated amount in another. Even the most favorable reviews call for larger studies and standardized methods. This is not a rejection: it is simply where a young field currently stands.

The skin barrier is the real testing ground

The skin is designed to limit the entry of external substances. Vesicles are nanoscale, but small size does not mean effective penetration: the ability to reach the viable layers depends on composition, surface charge, vehicle, barrier integrity, and stability in the product.

Then there are the practical questions—the ones I ask myself as a formulator. Do the vesicles survive production? Do they remain intact throughout their shelf life? Can they tolerate preservatives, temperature fluctuations, and contact with the other ingredients? Do they retain the same biological cargo from one batch to another?

Finally, there is an effect that causes a great deal of confusion: a formula can hydrate extremely well thanks to glycerin, hyaluronic acid, niacinamide, or beta-glucans present alongside the innovative technology. A positive experience does not tell you which component produced the result.

The regulatory point: in Europe, human origin changes everything

This is the information missing from almost every discussion on the subject, and it settles the matter better than any debate about effectiveness.

Regulation (EC) No 1223/2009 prohibits, under Annex II, entry 416, the use of «cells, tissues, or products of human origin» in cosmetics. Consequently, genuinely human exosomes or derivatives are not permitted ingredients in a cosmetic sold in the European Union. If a product marketed in Europe promises human exosomes, either it does not contain them or it is not a cosmetic.

Vesicles of plant, microbial, or synthetic origin are not subject to an equivalent ban, but they must still meet all the other requirements: safety assessment of the finished product, product information file, good manufacturing practices, notification, and claims supported by evidence.

In the United States, the boundary also depends on the intended use. The FDA has reiterated that there are no exosome-based products approved as regenerative therapies, and in May 2026 it renewed its warning about unapproved products derived from human cells or tissues—a reminder that mainly concerns preparations presented to treat diseases, not every plant-based cosmetic.

The decisive word remains the claim. Promising hydration or an improvement in the appearance of the skin falls within the cosmetics realm; declaring tissue regeneration, healing, or treatment of a disease moves the product into the field of medicinal products. It is a regulatory difference, not a nuance of language.

Five questions to ask a cosmetic that claims to contain exosomes

The first question is not «how many billion does it contain?», but «what exactly does it contain?».

1. What is the declared origin? Plant-based, bacterial, synthetic, and human origins are not interchangeable. Vague formulas such as "bioidentical" or "cell-derived" do not make the source and compliance clear.
2. Are they characterized vesicles or an inspired technology? A transparent company states whether it uses isolated vesicles, lysates, liposomes, or a biomimetic system. All are legitimate approaches, but they are different.
3. Is there a study on the finished product? An in vitro test on the raw material demonstrates a possible mechanism. To support a claim about the serum, data are needed on the formula actually sold, including quantity, frequency, duration, and measured parameters.
4. Was the test performed on intact skin? Results obtained after laser treatment or microneedling do not describe at-home use.
5. Are stability and storage documented? A vesicle that degrades in the bottle cannot do what it did in the laboratory. Packaging, temperature, and shelf life are not details.

From theory to practice: a restorative routine

The truly advanced approach is not to chase the latest trend, but to combine active ingredients supported by robust literature with any newer technologies, without turning the latter into miracle claims. LeLang focuses on evidence-based formulas without excessive claims: niacinamide for pores and sebum, enhanced vitamin C for radiance, peptides for firmness.

Radiance and an even skin tone

For radiance and mild discoloration, FeruliC + HA Serum combines ferulic acid and vitamin C with hyaluronic acid. Ferulic acid stabilizes vitamin C, which supports an even skin tone and collagen synthesis. Suitable for dull or photoaged skin.

Dynamic wrinkles and firmness

For fine lines and tone, the serum with Botoxil technology uses peptides with a smoothing action, such as argireline, to soften expression lines and support the skin matrix. Gradual results in elasticity and firmness, consistent with the literature on peptides.

Enlarged pores and texture

Cleansing Active Mousse from the Acnerebal line contains 0.5% salicylic acid, tea tree, burdock, and betaine. It unclogs pores, smooths the surface, and controls sebum without excessive dryness.

The treatment is completed by Acnerebal Serum, which helps reduce enlarged pores, and Acnerebal Cream, with a soothing action. The complete protocol is available in the guide to a routine for oily skin and enlarged pores.

Conclusion: promising, but the name is not enough

Exosomes are not a social media invention: they stem from more than forty years of research into cellular communication and have real potential in regenerative medicine. The first clinical studies on skin are interesting, especially as support for professional procedures.

Daily skincare, however, is a different matter. The origin of the vesicles, their ability to cross the barrier, formula stability, and reproducibility still need to be demonstrated product by product—and under the same label, biological, plant-based, microbial materials and systems merely inspired by exosomes coexist.

The right question is not whether exosomes work in absolute terms. It is: which vesicles, in what formula, applied how, and measured in which study?

In the meantime, ingredients such as niacinamide, hyaluronic acid, and vitamin C, when used with consistency and care, remain a highly effective solution for the topical treatment of many skin conditions. Consistency is key, along with choosing companies that are transparent about their evidence. You can also find LeLang products at partner pharmacies throughout the area, where someone can help you read a label before you buy.

Sources for this article

01 Welsh J.A. et al., Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches, Journal of Extracellular Vesicles, 2024; 13(2): e12404.
02 Kwon H.H. et al., Combination treatment with human adipose tissue stem cell-derived exosomes and fractional CO₂ laser for acne scars: a 12-week prospective, double-blind, randomized, split-face study, Acta Dermato-Venereologica, 2020; 100(18).
03 Park G.H. et al., prospective randomized study on microneedling and extracellular vesicles for facial aging, 2023 (PubMed, PMID 37377400).
04 Systematic review of the effectiveness of exosome-based therapies for skin rejuvenation, 2026 — twenty-one studies included.
05 Regulation (EC) No. 1223/2009 on cosmetic products, Annex II, entry 416.
06 FDA, Consumer warning about unapproved products derived from human cells or tissues, May 11, 2026.

On the website: peptides in cosmetics · skin barrier · hyaluronic acid · anti-aging collection